Amneal pharmaceuticals, inc. (AMRX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Net revenue

1,678,786

1,626,373

1,726,573

1,824,777

1,833,922

1,662,991

1,420,196

1,203,580

0

0

0

Cost of goods sold

1,151,049

1,147,214

1,177,961

1,178,811

1,117,922

938,773

754,373

621,944

0

0

0

Cost of goods sold impairment charges

74,321

126,162

112,441

64,124

61,112

7,815

0

0

0

-

-

Gross profit

453,416

352,997

436,171

581,842

654,888

716,403

658,008

581,636

0

0

0

Selling, general and administrative

283,138

289,598

286,750

298,439

287,161

227,846

184,050

135,502

0

0

0

Research and development

170,570

188,049

197,296

201,520

203,839

194,190

178,216

183,051

0

0

0

In-process research and development impairment charges

24,792

46,619

84,778

62,046

62,046

39,259

0

0

0

-

-

Intellectual property legal development expenses

11,342

14,238

12,500

14,315

15,851

16,261

19,717

20,242

0

0

0

Acquisition, transaction-related and integration expenses

12,931

16,388

17,627

16,727

220,715

221,818

219,144

216,995

0

0

0

Charges related to legal matters

-16,942

-12,442

-17,339

411

0

-

0

0

-

0

-

Restructuring and other charges

30,232

34,345

44,037

20,944

62,574

56,413

42,309

44,465

0

0

0

Operating income (loss)

-96,531

-248,682

-202,267

-15,438

-177,587

-19,673

35,800

5,848

0

0

0

Other (expense) income:
Interest expense, net

-164,823

-168,205

-172,256

-173,065

-165,801

-143,571

-119,909

-94,617

0

0

0

Foreign exchange loss, net

-4,679

-4,962

-6,867

527

-33,730

-19,701

-26,696

-6,227

0

0

0

Loss on extinguishment of debt

-

-

0

0

-

-

0

0

-

0

0

Gain on sale of international business

-1,560

7,258

6,784

3,972

5,860

-2,958

-31,692

0

0

0

-

Gain from reduction of tax receivable agreement liability

-

-

0

-

-

-

0

-

-

-

-

Other income, net

991

1,465

2,160

700

1,342

1,183

632

1,568

0

0

0

Total other expense, net

22,813

28,440

24,330

-166,201

-210,331

-183,049

-197,332

-150,354

0

0

0

Income (loss) before income taxes

-73,718

-220,242

-177,937

-181,639

-387,918

-202,722

-161,532

-144,506

0

0

0

Benefit from income taxes

283,331

383,331

381,455

-3,104

-9,819

-1,419

-7,645

-10,902

1,514

0

0

Net income (loss)

-357,304

-603,573

-559,000

-178,143

-377,707

-201,303

-153,851

-133,568

0

0

0

Less: Net loss (income) attributable to Amneal Pharmaceuticals LLC pre-Combination

-

-

0

0

-

-148,806

-122,026

-84,580

0

0

0

Less: Net (income) loss attributable to non-controlling interests

-158,335

-241,656

-220,443

-111,480

-109,741

-32,753

-20,849

-31,124

0

0

0

Net income (loss) attributable to Amneal Pharmaceuticals, Inc.

-198,969

-361,917

-322,901

-75,759

0

-

0

0

-

0

0

Accretion of redeemable non-controlling interest

-

-

0

0

-

-

0

0

-

0

0

Net loss attributable to Amneal Pharmaceuticals, Inc.

-

-

-338,557

-66,599

-

-20,920

-12,152

-19,104

0

0

0

Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.'s common stockholders:
Class A and Class B-1 basic

0.78

-

-2.03

-

-0.37

-

0.05

-

-

-

-

Class A and Class B-1 diluted

0.78

-

-2.03

-

-0.37

-

0.05

-

-

-

-

Class A and Class B-1 basic and diluted

-

-

-

-0.13

-

-

-

-0.15

-

-

-

Weighted-average common shares outstanding:
Class A and Class B-1 basic

147,180

-

130,729

-

127,687

-

127,247

-

-

-

-

Class A and Class B-1 diluted

147,956

-

130,729

-

127,687

-

128,222

-

-

-

-

Class A and Class B-1 basic and diluted

-

-

-

128,016

-

-

-

127,112

-

-

0